_id
691854bc3c536f8df23178d8
Ticker
0EVI.LSE
Name
Innate Pharma S.A.
Exchange
LSE
Address
117, Avenue de Luminy, Marseille, France, 13009
Country
UK
Sector
Industry
Currency
EUR
Website
https://www.innate-pharma.com
Description
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
Last Close
1.542
Volume
17400
Current Price
1.552
Change
0.006
Last Updated
2026-01-08T13:40:11.003Z
Image
https://logo.clearbit.com/www.innate-pharma.com
Ipo Date
-
Market Cap
193877584
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2023-06-30
Revenue
-
Cost Of Revenue
-
Gross Profit
-
Operating Expenses
-
Operating Income
-
Interest Expense
-
Pretax Income
-
Net Income
-
Eps
-
Dividends Per Share
-
Shares Outstanding
57581400
Income Tax Expense
-
EBITDA
-
Operating Margin
-
Total Other Income Expense Net
-
Cash
-
Short Term Investments
-
Receivables
49092000
Inventories
-
Total Current Assets
144455000
Property Plant Equipment
7262000
Total Assets
-
Payables
9868000
Short Term Debt
-
Long Term Debt
-
Total Liabilities
37667000
Equity
-
Bs_currency_symbol
EUR
Depreciation
1822500
Change In Working Capital
-
Cash From Operations
-5732500
Capital Expenditures
154500
Cash From Investing
-123000
Cash From Financing
-623000
Net Change In Cash
-6405500
Cf_currency_symbol
EUR
PE
-
PB
-
ROE
-
ROA
-
FCF
-5887000
Fcf Percent
-
Piotroski FScore
0
Health Score
45
Deep Value Investing Score
0
Defensive Investing Score
5
Dividend Investing Score
1.5
Economic Moat Investing Score
1
Garp Investing Score
0
Growth Investing Score
0
Momentum Investing Score
2
Net Net Investing Score
0
Quality Investing Score
0
Value Investing Score
1.5
Quarters > 0 > quarter
2023-06-30
Quarters > 0 > income Statement > revenue
-
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
-
Quarters > 0 > income Statement > operating Expenses
-
Quarters > 0 > income Statement > operating Income
-
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-
Quarters > 0 > income Statement > net Income
-
Quarters > 0 > income Statement > eps
-
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
-
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
-
Quarters > 0 > income Statement > currency_symbol
EUR
Quarters > 0 > balance Sheet > cash
-
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
49092000
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
144455000
Quarters > 0 > balance Sheet > property Plant Equipment
7262000
Quarters > 0 > balance Sheet > total Assets
-
Quarters > 0 > balance Sheet > payables
9868000
Quarters > 0 > balance Sheet > short Term Debt
-
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
37667000
Quarters > 0 > balance Sheet > equity
-
Quarters > 0 > balance Sheet > currency_symbol
EUR
Quarters > 0 > cash Flow > net Income
859000
Quarters > 0 > cash Flow > depreciation
1822500
Quarters > 0 > cash Flow > change In Working Capital
-
Quarters > 0 > cash Flow > cash From Operations
-5732500
Quarters > 0 > cash Flow > capital Expenditures
154500
Quarters > 0 > cash Flow > cash From Investing
-123000
Quarters > 0 > cash Flow > cash From Financing
-623000
Quarters > 0 > cash Flow > net Change In Cash
-6405500
Quarters > 0 > cash Flow > currency_symbol
EUR
Quarters > 0 > ratios > PE
-
Quarters > 0 > ratios > PB
-
Quarters > 0 > ratios > ROE
-
Quarters > 0 > ratios > ROA
-
Quarters > 0 > ratios > FCF
-5887000
Quarters > 0 > ratios > Piotroski FScore
0
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
45
Quarters > 1 > quarter
2023-03-31
Quarters > 1 > income Statement > revenue
-
Quarters > 1 > income Statement > cost Of Revenue
-
Quarters > 1 > income Statement > gross Profit
-
Quarters > 1 > income Statement > operating Expenses
-
Quarters > 1 > income Statement > operating Income
-
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-
Quarters > 1 > income Statement > net Income
-
Quarters > 1 > income Statement > eps
-
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
-
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
-
Quarters > 1 > income Statement > currency_symbol
EUR
Quarters > 1 > balance Sheet > cash
-
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
49092000
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
144455000
Quarters > 1 > balance Sheet > property Plant Equipment
7262000
Quarters > 1 > balance Sheet > total Assets
-
Quarters > 1 > balance Sheet > payables
9868000
Quarters > 1 > balance Sheet > short Term Debt
-
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
37667000
Quarters > 1 > balance Sheet > equity
-
Quarters > 1 > balance Sheet > currency_symbol
EUR
Quarters > 1 > cash Flow > net Income
859000
Quarters > 1 > cash Flow > depreciation
1822500
Quarters > 1 > cash Flow > change In Working Capital
-
Quarters > 1 > cash Flow > cash From Operations
-5732500
Quarters > 1 > cash Flow > capital Expenditures
154500
Quarters > 1 > cash Flow > cash From Investing
-123000
Quarters > 1 > cash Flow > cash From Financing
-623000
Quarters > 1 > cash Flow > net Change In Cash
-6405500
Quarters > 1 > cash Flow > currency_symbol
EUR
Quarters > 1 > ratios > PE
-
Quarters > 1 > ratios > PB
-
Quarters > 1 > ratios > ROE
-
Quarters > 1 > ratios > ROA
-
Quarters > 1 > ratios > FCF
-5887000
Quarters > 1 > ratios > Piotroski FScore
0
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
45
Quarters > 2 > quarter
2022-12-31
Quarters > 2 > income Statement > revenue
-
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
-
Quarters > 2 > income Statement > operating Expenses
-
Quarters > 2 > income Statement > operating Income
-
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-
Quarters > 2 > income Statement > net Income
-
Quarters > 2 > income Statement > eps
-
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
-
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
-
Quarters > 2 > income Statement > currency_symbol
EUR
Quarters > 2 > balance Sheet > cash
-
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
38346000
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
139831000
Quarters > 2 > balance Sheet > property Plant Equipment
8542000
Quarters > 2 > balance Sheet > total Assets
-
Quarters > 2 > balance Sheet > payables
20911000
Quarters > 2 > balance Sheet > short Term Debt
-
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
41338000
Quarters > 2 > balance Sheet > equity
-
Quarters > 2 > balance Sheet > currency_symbol
EUR
Quarters > 2 > cash Flow > net Income
-32203000
Quarters > 2 > cash Flow > depreciation
21687500
Quarters > 2 > cash Flow > change In Working Capital
-
Quarters > 2 > cash Flow > cash From Operations
-10186000
Quarters > 2 > cash Flow > capital Expenditures
57500
Quarters > 2 > cash Flow > cash From Investing
1136000
Quarters > 2 > cash Flow > cash From Financing
-434000
Quarters > 2 > cash Flow > net Change In Cash
-9362000
Quarters > 2 > cash Flow > currency_symbol
EUR
Quarters > 2 > ratios > PE
-
Quarters > 2 > ratios > PB
-
Quarters > 2 > ratios > ROE
-
Quarters > 2 > ratios > ROA
-
Quarters > 2 > ratios > FCF
-10243500
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
45
Quarters > 3 > quarter
2022-09-30
Quarters > 3 > income Statement > revenue
-
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
-
Quarters > 3 > income Statement > operating Expenses
-
Quarters > 3 > income Statement > operating Income
-
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-
Quarters > 3 > income Statement > net Income
-
Quarters > 3 > income Statement > eps
-
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
-
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
-
Quarters > 3 > income Statement > currency_symbol
EUR
Quarters > 3 > balance Sheet > cash
-
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
38346000
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
139831000
Quarters > 3 > balance Sheet > property Plant Equipment
8542000
Quarters > 3 > balance Sheet > total Assets
-
Quarters > 3 > balance Sheet > payables
20911000
Quarters > 3 > balance Sheet > short Term Debt
-
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
41338000
Quarters > 3 > balance Sheet > equity
-
Quarters > 3 > balance Sheet > currency_symbol
EUR
Quarters > 3 > cash Flow > net Income
-32203000
Quarters > 3 > cash Flow > depreciation
21687500
Quarters > 3 > cash Flow > change In Working Capital
-
Quarters > 3 > cash Flow > cash From Operations
-10186000
Quarters > 3 > cash Flow > capital Expenditures
57500
Quarters > 3 > cash Flow > cash From Investing
1136000
Quarters > 3 > cash Flow > cash From Financing
-434000
Quarters > 3 > cash Flow > net Change In Cash
-9362000
Quarters > 3 > cash Flow > currency_symbol
EUR
Quarters > 3 > ratios > PE
-
Quarters > 3 > ratios > PB
-
Quarters > 3 > ratios > ROE
-
Quarters > 3 > ratios > ROA
-
Quarters > 3 > ratios > FCF
-10243500
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
45
Annuals > 0 > quarter
2022-12-31
Annuals > 0 > income Statement > revenue
-
Annuals > 0 > income Statement > cost Of Revenue
-
Annuals > 0 > income Statement > gross Profit
-
Annuals > 0 > income Statement > operating Expenses
-
Annuals > 0 > income Statement > operating Income
-
Annuals > 0 > income Statement > interest Expense
-
Annuals > 0 > income Statement > pretax Income
-
Annuals > 0 > income Statement > net Income
-
Annuals > 0 > income Statement > eps
-
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
-
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
-
Annuals > 0 > income Statement > currency_symbol
EUR
Annuals > 0 > balance Sheet > cash
-
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
38346000
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
139831000
Annuals > 0 > balance Sheet > property Plant Equipment
8542000
Annuals > 0 > balance Sheet > total Assets
-
Annuals > 0 > balance Sheet > payables
20911000
Annuals > 0 > balance Sheet > short Term Debt
-
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
41338000
Annuals > 0 > balance Sheet > equity
-
Annuals > 0 > balance Sheet > currency_symbol
EUR
Annuals > 0 > cash Flow > net Income
-58103000
Annuals > 0 > cash Flow > depreciation
45405000
Annuals > 0 > cash Flow > change In Working Capital
-
Annuals > 0 > cash Flow > cash From Operations
-19154000
Annuals > 0 > cash Flow > capital Expenditures
535000
Annuals > 0 > cash Flow > cash From Investing
1877000
Annuals > 0 > cash Flow > cash From Financing
-1828000
Annuals > 0 > cash Flow > net Change In Cash
-19531000
Annuals > 0 > cash Flow > currency_symbol
EUR
Annuals > 0 > ratios > PE
-
Annuals > 0 > ratios > PB
-
Annuals > 0 > ratios > ROE
-
Annuals > 0 > ratios > ROA
-
Annuals > 0 > ratios > FCF
-19689000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
45
Annuals > 1 > quarter
2021-12-31
Annuals > 1 > income Statement > revenue
-
Annuals > 1 > income Statement > cost Of Revenue
-
Annuals > 1 > income Statement > gross Profit
-
Annuals > 1 > income Statement > operating Expenses
-
Annuals > 1 > income Statement > operating Income
-
Annuals > 1 > income Statement > interest Expense
0
Annuals > 1 > income Statement > pretax Income
-
Annuals > 1 > income Statement > net Income
-
Annuals > 1 > income Statement > eps
-
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
-
Annuals > 1 > income Statement > income Tax Expense
-
Annuals > 1 > income Statement > EBITDA
-
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
-
Annuals > 1 > income Statement > currency_symbol
EUR
Annuals > 1 > balance Sheet > cash
-
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
13474000
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
138256000
Annuals > 1 > balance Sheet > property Plant Equipment
10174000
Annuals > 1 > balance Sheet > total Assets
-
Annuals > 1 > balance Sheet > payables
14730000
Annuals > 1 > balance Sheet > short Term Debt
-
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
79886000
Annuals > 1 > balance Sheet > equity
-
Annuals > 1 > balance Sheet > currency_symbol
EUR
Annuals > 1 > cash Flow > net Income
-52809000
Annuals > 1 > cash Flow > depreciation
4596000
Annuals > 1 > cash Flow > change In Working Capital
-
Annuals > 1 > cash Flow > cash From Operations
-58457000
Annuals > 1 > cash Flow > capital Expenditures
929000
Annuals > 1 > cash Flow > cash From Investing
-917000
Annuals > 1 > cash Flow > cash From Financing
26818000
Annuals > 1 > cash Flow > net Change In Cash
-33037000
Annuals > 1 > cash Flow > currency_symbol
EUR
Annuals > 1 > ratios > PE
-
Annuals > 1 > ratios > PB
-
Annuals > 1 > ratios > ROE
-
Annuals > 1 > ratios > ROA
-
Annuals > 1 > ratios > FCF
-59386000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
45
Annuals > 2 > quarter
2020-12-31
Annuals > 2 > income Statement > revenue
56155000
Annuals > 2 > income Statement > cost Of Revenue
3638000
Annuals > 2 > income Statement > gross Profit
52517000
Annuals > 2 > income Statement > operating Expenses
-
Annuals > 2 > income Statement > operating Income
-62076000
Annuals > 2 > income Statement > interest Expense
0
Annuals > 2 > income Statement > pretax Income
-63984000
Annuals > 2 > income Statement > net Income
-63984000
Annuals > 2 > income Statement > eps
-
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
-
Annuals > 2 > income Statement > income Tax Expense
-
Annuals > 2 > income Statement > EBITDA
-
Annuals > 2 > income Statement > operating Margin
-110.54402991719347
Annuals > 2 > income Statement > total Other Income Expense Net
-
Annuals > 2 > income Statement > currency_symbol
EUR
Annuals > 2 > balance Sheet > cash
136792000
Annuals > 2 > balance Sheet > short Term Investments
14845000
Annuals > 2 > balance Sheet > receivables
13867000
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
173451000
Annuals > 2 > balance Sheet > property Plant Equipment
11694000
Annuals > 2 > balance Sheet > total Assets
307423000
Annuals > 2 > balance Sheet > payables
20731000
Annuals > 2 > balance Sheet > short Term Debt
1828000
Annuals > 2 > balance Sheet > long Term Debt
59043000
Annuals > 2 > balance Sheet > total Liabilities
151447000
Annuals > 2 > balance Sheet > equity
155976000
Annuals > 2 > balance Sheet > currency_symbol
EUR
Annuals > 2 > cash Flow > net Income
-63984000
Annuals > 2 > cash Flow > depreciation
13268000
Annuals > 2 > cash Flow > change In Working Capital
-48865000
Annuals > 2 > cash Flow > cash From Operations
-51767000
Annuals > 2 > cash Flow > capital Expenditures
907000
Annuals > 2 > cash Flow > cash From Investing
-13370000
Annuals > 2 > cash Flow > cash From Financing
-1177000
Annuals > 2 > cash Flow > net Change In Cash
-66096000
Annuals > 2 > cash Flow > currency_symbol
EUR
Annuals > 2 > ratios > PE
-
Annuals > 2 > ratios > PB
-
Annuals > 2 > ratios > ROE
-41.021695645483916
Annuals > 2 > ratios > ROA
-20.813016592772822
Annuals > 2 > ratios > FCF
-52674000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-0.9380108627904906
Annuals > 2 > health Score
31
Annuals > 3 > quarter
2019-12-31
Annuals > 3 > income Statement > revenue
68974000
Annuals > 3 > income Statement > cost Of Revenue
3208000
Annuals > 3 > income Statement > gross Profit
65766000
Annuals > 3 > income Statement > operating Expenses
-
Annuals > 3 > income Statement > operating Income
-27052000
Annuals > 3 > income Statement > interest Expense
0
Annuals > 3 > income Statement > pretax Income
-20759000
Annuals > 3 > income Statement > net Income
-20759000
Annuals > 3 > income Statement > eps
-
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
-
Annuals > 3 > income Statement > income Tax Expense
-
Annuals > 3 > income Statement > EBITDA
-
Annuals > 3 > income Statement > operating Margin
-39.220575869168094
Annuals > 3 > income Statement > total Other Income Expense Net
-
Annuals > 3 > income Statement > currency_symbol
EUR
Annuals > 3 > balance Sheet > cash
202887000
Annuals > 3 > balance Sheet > short Term Investments
15978000
Annuals > 3 > balance Sheet > receivables
13140000
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
237605000
Annuals > 3 > balance Sheet > property Plant Equipment
11672000
Annuals > 3 > balance Sheet > total Assets
401361000
Annuals > 3 > balance Sheet > payables
27936000
Annuals > 3 > balance Sheet > short Term Debt
21304000
Annuals > 3 > balance Sheet > long Term Debt
14101000
Annuals > 3 > balance Sheet > total Liabilities
183945000
Annuals > 3 > balance Sheet > equity
217416000
Annuals > 3 > balance Sheet > currency_symbol
EUR
Annuals > 3 > cash Flow > net Income
-20759000
Annuals > 3 > cash Flow > depreciation
16529000
Annuals > 3 > cash Flow > change In Working Capital
40448000
Annuals > 3 > cash Flow > cash From Operations
34924000
Annuals > 3 > cash Flow > capital Expenditures
1271000
Annuals > 3 > cash Flow > cash From Investing
-62121000
Annuals > 3 > cash Flow > cash From Financing
77765000
Annuals > 3 > cash Flow > net Change In Cash
50573000
Annuals > 3 > cash Flow > currency_symbol
EUR
Annuals > 3 > ratios > PE
-
Annuals > 3 > ratios > PB
-
Annuals > 3 > ratios > ROE
-9.548055340913272
Annuals > 3 > ratios > ROA
-5.172151753658178
Annuals > 3 > ratios > FCF
33653000
Annuals > 3 > ratios > Piotroski FScore
2
Annuals > 3 > ratios > fcf Percent
0.4879084872560675
Annuals > 3 > health Score
51
Valuation > final Score
50
Valuation > verdict
Fair
Profitability > final Score
50
Profitability > verdict
Weak
Risk > final Score
50
Risk > verdict
High
Liquidity > metrics > Current Ratio
14.638731252533441
Liquidity > metrics > Quick Ratio
14.638731252533441
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
50
Prev Valuations > 1
50
Prev Valuations > 2
50
Prev Profitabilities > 0
50
Prev Profitabilities > 1
50
Prev Profitabilities > 2
50
Prev Risks > 0
50
Prev Risks > 1
50
Prev Risks > 2
50
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T22:52:35.960Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-03-26
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
AfterMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
Stock Price
€0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2023-06-30)
Health Score
* Institutions hold a combined 0.00% of the total shares of Innate Pharma S.A.
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
—
Date
—
EPS Actual
—
EPS Estimate
—
EPS Difference
—
Surprise Percent
undefined%
(Last Updated 2023-06-30)
(Last Updated 2023-06-30)
Revenue
€ 0
Cost Of Revenue
€ 0
Gross Profit
€ 0
Operating Expenses
€ 0
Operating Income
€ 0
Interest Expense
€ 0
Pretax Income
€ 0
Net Income
€ 0
Income Tax Expense
€ 0
EBITDA
€ 0
Total Other Income Expense Net
€ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2023-06-30)
Cash
€ 0
Short Term Investments
€ 0
Receivables
€ 0
Inventories
€ 0
Total Current Assets
€ 0
Property Plant Equipment
€ 0
Total Assets
€ 0
Payables
€ 0
Short Term Debt
€ 0
Long Term Debt
€ 0
Total Liabilities
€ 0
Equity
€ 0
(Last Updated 2023-06-30)
Net Income
€ 0
Depreciation
€ 0
Change In Working Capital
€ 0
Cash From Operations
€ 0
Capital Expenditures
€ 0
Cash From Investing
€ 0
Cash From Financing
€ 0
Net Change In Cash
€ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.